Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.310
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

Omalizumab Treatment in Brittle Asthma

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Lengthening Omalizumab Dosing Interval in Treatment of Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Omalizumab Treatment in Patients With Chronic Spontaneous Urticaria

Bőrgyógyászati és Venerológiai Szemle
2015English

Omalizumab and Mepolizumab in the Landscape of Biological Therapy for Severe Asthma in Children: How to Choose?

Italian Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy